7/7, 1:19 PM (Source: TeleTrader)
more TeleTrader news

Corvus Pharma soars 150% as it starts COVID-19 immunotherapy trial

Shares of Corvus Pharmaceuticals skyrocketed over 150% in premarket trading on Tuesday after the company announced it is starting a clinical trial of its COVID-19 therapy.

Corvus said it initiated a Phase 1 trial of its novel immunotherapy for coronavirus patients which will include up to 30 participants in the United States. "Our B cell-activating monoclonal antibody may be a potential immunotherapy for COVID-19 based on its ability to stimulate the production of anti-SARS-CoV-2 antibodies," Corvus CEO Richard A. Miller stated.

Corvus' stock soared 153.28% at 7:16 am ET to $6.63.

Breaking the News / NP